Literature DB >> 11850637

Crystal structure of the human TbetaR2 ectodomain--TGF-beta3 complex.

P John Hart1, Shashank Deep, Alexander B Taylor, Zhanyong Shu, Cynthia S Hinck, Andrew P Hinck.   

Abstract

Transforming growth factor-beta (TGF-beta) is the prototype of a large family of structurally related cytokines that play key roles in maintaining cellular homeostasis by signaling through two classes of functionally distinct Ser/Thr kinase receptors, designated as type I and type II. TGF-beta initiates receptor assembly by binding with high affinity to the type II receptor. Here, we present the 2.15 A crystal structure of the extracellular ligand-binding domain of the human TGF-beta type II receptor (ecTbetaR2) in complex with human TGF-beta3. ecTbetaR2 interacts with homodimeric TGF-beta3 by binding identical finger segments at opposite ends of the growth factor. Relative to the canonical 'closed' conformation previously observed in ligand structures across the superfamily, ecTbetaR2-bound TGF-beta3 shows an altered arrangement of its monomeric subunits, designated the 'open' conformation. The mode of TGF-beta3 binding shown by ecTbetaR2 is compatible with both ligand conformations. This, in addition to the predicted mode for TGF-beta binding to the type I receptor ectodomain (ecTbetaR1), suggests an assembly mechanism in which ecTbetaR1 and ecTbetaR2 bind at adjacent positions on the ligand surface and directly contact each other via protein--protein interactions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11850637     DOI: 10.1038/nsb766

Source DB:  PubMed          Journal:  Nat Struct Biol        ISSN: 1072-8368


  81 in total

1.  Structures of an ActRIIB:activin A complex reveal a novel binding mode for TGF-beta ligand:receptor interactions.

Authors:  Thomas B Thompson; Teresa K Woodruff; Theodore S Jardetzky
Journal:  EMBO J       Date:  2003-04-01       Impact factor: 11.598

2.  Osteocyte control of bone formation via sclerostin, a novel BMP antagonist.

Authors:  David G Winkler; May Kung Sutherland; James C Geoghegan; Changpu Yu; Trenton Hayes; John E Skonier; Diana Shpektor; Mechtild Jonas; Brian R Kovacevich; Karen Staehling-Hampton; Mark Appleby; Mary E Brunkow; John A Latham
Journal:  EMBO J       Date:  2003-12-01       Impact factor: 11.598

3.  Sequential resonance assignments of the extracellular domain of the human TGFbeta type II receptor in complex with monomeric TGFbeta3.

Authors:  Udayar Ilangovan; Shashank Deep; Cynthia S Hinck; Andrew P Hinck
Journal:  J Biomol NMR       Date:  2004-05       Impact factor: 2.835

4.  Computational alanine scanning with linear scaling semiempirical quantum mechanical methods.

Authors:  David J Diller; Christine Humblet; Xiaohua Zhang; Lance M Westerhoff
Journal:  Proteins       Date:  2010-08-01

5.  Peptide ligands that use a novel binding site to target both TGF-β receptors.

Authors:  Lingyin Li; Brendan P Orner; Tao Huang; Andrew P Hinck; Laura L Kiessling
Journal:  Mol Biosyst       Date:  2010-10-04

6.  Characterization of follistatin-type domains and their contribution to myostatin and activin A antagonism.

Authors:  Jennifer N Cash; Elizabeth B Angerman; Henry T Keutmann; Thomas B Thompson
Journal:  Mol Endocrinol       Date:  2012-05-16

Review 7.  Identifying protein interactors in gonadotropin action.

Authors:  James A Dias; Cheryl A Nechamen; Raghad Atari
Journal:  Endocrine       Date:  2005-04       Impact factor: 3.633

Review 8.  The microRNA networks of TGFβ signaling in cancer.

Authors:  V P Sivadas; S Kannan
Journal:  Tumour Biol       Date:  2013-12-10

9.  A cytokine-neutralizing antibody as a structural mimetic of 2 receptor interactions.

Authors:  Christian Grütter; Trevor Wilkinson; Richard Turner; Sadhana Podichetty; Donna Finch; Matthew McCourt; Scott Loning; Lutz Jermutus; Markus G Grütter
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-10       Impact factor: 11.205

10.  Members of the DAN family are BMP antagonists that form highly stable noncovalent dimers.

Authors:  Chandramohan Kattamuri; David M Luedeke; Kristof Nolan; Scott A Rankin; Kenneth D Greis; Aaron M Zorn; Thomas B Thompson
Journal:  J Mol Biol       Date:  2012-10-09       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.